bullish
Jacobio Pharma: More Thinking on Valuation
372 Views21 Nov 2020 00:08
Our DCF analysis of Jacobio Pharma results in a US$1.1B pre-money valuation based on the company's lead compounds and the AbbVie license agreement. We also include questions for management.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
x